Published in final edited form as:

Trends Biotechnol. 2014 November ; 32(11): 556–563. doi:10.1016/j.tibtech.2014.09.006.

Methods to study the tumor microenvironment under controlled oxygen conditions

Matthew B. Byrne^{1,2}, Matthew T. Leslie^{2,4}, H. Rex Gaskins^{2,3,4}, and Paul J.A. Kenis^{1,2}

¹ Department of Chemical & Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA

² Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA

³ Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA

⁴ Department of Pathobiology; University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA

Abstract

The tumor microenvironment is a complex heterogeneous assembly composed of a variety of cell types and physical features. One such feature, hypoxia, is associated with metabolic reprogramming, the epithelial-mesenchymal transition, and therapeutic resistance. Many questions remain regarding the effects of hypoxia on these outcomes, yet only few experimental methods enable both precise control over oxygen concentration and real-time imaging of cell behavior. Recent efforts with microfluidic platforms offer a promising solution to these limitations. We discuss conventional methods and tools used to control oxygen concentration for cell studies then highlight recent advances in microfluidic-based approaches for controlling oxygen in engineered platforms.

Keywords

Hypoxia; Microfluidics; Tumor Microenvironment

Studying hypoxia in the tumor microenvironment

Molecular oxygen is used as a terminal electron acceptor in cellular respiration by most heterotrophic eukaryotes. Due to a variety of factors, including the transport of oxygen via diffusion, oxygen concentration gradients often exist within tissues [1]. When the transport of oxygen is unable to meet demand, hypoxia (sub-physiologic tissue oxygenation) occurs [2]. The partial pressure of oxygen in one such location where hypoxia is often found, the

© 2014 Elsevier Ltd. All rights reserved

Corresponding author: Kenis, P.J.A. (kenis@illinois.edu). Gaskins, H.R. (hgaskins@illinois.edu).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

tumor microenvironment, ranges from 2 mm Hg (0.3% O₂) to 15 mm Hg (2.1% O₂) depending on tumor type (Table 1) [3, 4]. Comparatively, arterial blood has a partial pressure of oxygen of 100 mm Hg (13.1% O₂), and the partial pressure introduced into traditional cell culture is 152 mm Hg (20% O₂) [5]. Thus, to support the transition between *in vitro* knowledge and clinical successes, and to more accurately mimic oxygen conditions seen *in vivo*, advanced platforms of study are needed to more closely recapitulate hypoxia in the TME (Box 1) and tissue in general.

Controlling oxygen conditions in a laboratory setting is challenging due to sample/reagent handling and constant diffusion of oxygen from ambient air ($\approx 21\%$). For example, each step during an experiment must be performed under identical oxygen conditions to prevent bias and to ensure reproducibility. A standard laboratory practice such as changing media for cells requires the cell culture flask to be removed from a gas-controlled incubator and placed in a chamber with the same desired oxygen concentration. Further, fresh media must be pre-equilibrated to the same oxygen concentration. The dissolved oxygen concentration in the reagent, in this case media, should also be measured prior to addition. Hence, executing a series of relatively simple laboratory techniques quickly becomes arduous under controlled oxygen concentrations.

To control the gaseous environment for cell studies, a number of conventional methods are used. The two most common methods (Figure 1), enable *in vitro* cell assays under hypoxia by (i) having a chamber with an air-tight seal and introducing specific gas concentrations, or by (ii) biochemically inducing a state of pseudo-hypoxia within the cell. These two methods provide unique benefits as well as limitations for cell assays under hypoxia.

Perhaps the most prevalent method to control the oxygen concentration is modulation of the gas mixtures entering an incubator (Figure 1A). In this method, cells are grown and conditioned in an incubator with the desired oxygen concentration [6]. However, long oxygen equilibration periods and the burdensome measures taken to sustain hypoxia throughout all aspects of experimentation limit the effectiveness of this method. Further, gas-controlled incubators require an additional system for manual handling of reagents such as a glove box. Similar tools such as hypoxia chambers have equivalent limitations when requiring real-time imaging or reagent manipulation [7]. To enable live imaging, perfusion chambers have been used in conjunction with microscopy to enable analysis of real-time data [8]. These perfusion chambers work by limiting diffusion of ambient air into the cell channel. The oxygen conditions are modulated by introducing liquids with a pre-equilibrated dissolved oxygen concentration into the chamber. However, handling and use of the reagents after equilibration of oxygen concentration is imprecise and challenging due to diffusion of oxygen from ambient air. Further, current studies using this system have required cells to adhere to a microscope slide and, thus, the cells were not grown in a three-dimensional (3D) environment. While providing cells a 3D environment may be possible when using perfusion chambers, current studies have relied on 2D cultures. As such, this limitation may affect cell behavior as 3D cell cultures are more physiologically relevant and have been found to differ significantly from 2D cultures in proliferation, migration, and expression of cell-surface receptors [9-11].

A second approach used to study cellular responses to hypoxia is by biochemically inducing a pseudo-hypoxic state in cells (Figure 1B). This method is distinct from others as the aqueous solution remains oxygenated while investigators rely upon chemical treatments to induce signaling events associated with hypoxia. A number of chemicals such as prolyl hydroxylase inhibitors, nickel chloride, and, the most widely used chemical inducer of hypoxia, cobalt chloride, stabilize the transcription factor hypoxia inducible factor 1- α (HIF-1 α) (Box 2) and thus mimic hypoxia [6, 12-16]. The two proposed mechanisms by which cobalt chloride stabilizes HIF-1 α include inactivating prolyl hydroxylases by chelating their iron core and replacing it with cobalt [17], or by taking up the VHL-binding domain of HIF- α , thus rescuing it from degradation [18]. In either case, this state of pseudo-hypoxia has proven to be useful for many biochemical analyses as oxygen can be present in samples without affecting the experiment. However, this biochemical induction narrows the scope of the hypoxic study to those events downstream of the single HIF family of transcription factors. While HIF's are master regulators of many hypoxic cell responses, cobalt chloride fails to adequately reproduce mitochondrial ROS signaling, rather generation of ROS from cobalt chloride physiologically differs from that of hypoxic ROS generation [19, 20]. Furthermore, cobalt itself is cytotoxic [21], and cobalt chloride affects cell division and morphology [22], while in some cases inducing mitochondrial DNA damage and apoptosis [23, 24]. Overall, these conventional methods are limited in their ability to support the study of cell behavior under controlled oxygen conditions.

Microfluidic platforms for hypoxic studies

Microfluidic platforms enable precise control over the local microenvironment. This inherent characteristic allows spatial and temporal regulation of specific chemical and gaseous conditions. For example, microfluidic platforms capable of creating chemical concentration gradients have been used for cell migration studies [25, 26]. Further, spatiotemporal control over signaling molecules has enabled studies on cell-cell communication between multiple cell populations [27, 28]. In addition to control over the microenvironment, a key aspect of microfluidic platforms is that equilibration times are significantly reduced compared to conventional methods due to differences in scale (micro vs. macro) [7, 29]. To control the oxygen concentration inside microfluidic platforms, several different mechanisms have been employed. The three most common methods (Figure 2) are (i) introducing oxygen scavenging chemicals into the platform [30, 31], (ii) controlling oxygen supply by implementing adjacent gas supply channels, *e.g.*, in multilayer platforms [29, 32-39], and (iii) reducing oxygen supply by use of oxygen impermeable materials such as cyclic olefin copolymer (COC), polystyrene (PS), or poly(methyl methacrylate) (PMMA) [40-44]. A few other microfluidic approaches to control oxygen tension have been reported [42, 45-47], but they are challenging to fabricate or more cumbersome in operation. The remainder of this review focuses mostly on the three aforementioned microfluidic methods of controlling oxygen concentration.

Oxygen scavenging chemicals

One method to control oxygen concentration in the microfluidic platform utilizes oxygen scavenging chemicals (Figure 2A). On a macroscale, oxygen scavenging chemicals have

been used to control oxygen concentration in solutions [48]. However, temporal and spatial heterogeneity exist due to long diffusion times and a lack of control over mixing of the chemical solutions (convective mixing). In microfluidic platforms, mixing occurs only via diffusion due to fluid flow being in the laminar flow regime. Hence, the concentration and reaction rate of oxygen scavenging chemicals can be controlled well. Oxygen concentration gradients have been created by generating oxygen scavenging and oxygen generating reactions on either side of a cell channel [30]. Similarly, modulating channel dimensions and sodium sulfite flow rates enabled control over the oxygen concentration in a cell channel [31]. Utilizing the developed platforms, the anti-cancer drug Tirapazamine was tested under various oxygen concentrations on ardenocarcinomic human alveolar basal epithelial (A549) cells demonstrating the utility of these platforms for therapeutic testing [30, 31]. In addition, by introducing oxygen scavenging chemicals rather than gas streams, ancillaries such as gas cylinders and flow controllers are not required. However, the continuous flow associated with this method requires syringe pumps or passive pumping techniques such as gravity-driven flow and surface-tension driven flow to introduce the oxygen scavenging (or generating) chemicals into the platform.

Gas supply channels

The second method to control oxygen concentration is based on implementing gas supply channels adjacent to cell chambers (Figure 2B). An advantage of microfluidic platforms is their ability to be designed and rapidly fabricated to meet desired specifications. Hence, development of platforms with optimal positioning of gas channels enables control over oxygen concentration. The most common geometric arrangement of gas supply channels utilizes multilayer platforms, with the gas channel flowing over or under a monolayer of cells [29, 35-38]. These platforms have been used to study intracellular calcium dynamics in neonatal rat cardiomyocytes under hypoxia [29]. Aqueous solutions with pre-equilibrated oxygen concentration have been introduced offering the additional advantage of reducing changes in solute concentration [34]. However, this method of pre-equilibrating aqueous solutions is imprecise and challenging due to diffusion of oxygen from ambient air during handling. In addition, these multilayer platforms can be more difficult to fabricate and use than single-layer platforms. For example, care must be taken that features in control layers do not obstruct imaging of cells.

Modifications to standard laboratory tools such as the Boyden chamber [49] and well plates [50] have been developed to control oxygen tension. These structures, commonly composed of poly(dimethylsiloxane) (PDMS) and created via replica molding, provide gas channels above the cell culture chamber. Similar to a well plate, cell chambers open to the atmosphere have been developed to control oxygen by flowing gas or oxygen scavenging chemicals underneath the cells [32, 39]. This open well platform has been used to study intracellular reactive oxygen species (ROS) levels in Madin-Darby Canine Kidney (MDCK) cells under oxygen gradients [32]. These platforms enable easy addition of chemicals and are similar to a conventional tissue culture dish. The platforms require cells to adhere to PDMS in a monolayer to have a uniform oxygen concentration for all cells. To overcome the limitation of cells cultured on PDMS in 2D, a microfluidic platform capable of culturing cells in a 3D microenvironment while controlling the oxygen concentration was developed by positioning

gas channels both above and below the cell chamber [33]. Overall, introducing gas supply channels adjacent to cell chambers has proven to be an effective method to control oxygen concentration. However, further advances in user operability are necessary for this method to gain widespread use.

Oxygen impermeable materials

A third method to control oxygen concentration is by fabricating platforms out of oxygen impermeable materials (Figure 2B). Traditionally, microfluidic platforms have been fabricated using PDMS. One of the main benefits of using PDMS is ease and speed of replica molding, allowing for rapid iteration in design improvements. During cell culture, PDMS enables diffusion of oxygen from the atmosphere into cell channels. However when desiring hypoxic conditions, this oxygen permeability limits the ability to control oxygen tension. To combat this issue, materials with low oxygen permeability (Table 2) can be selected and used to fabricate platforms. Oxygen diffusivity is orders of magnitude higher in PDMS than the other materials listed. Hence, microfluidic platforms comprised of alternative materials have the potential to control oxygen concentration more effectively by reducing diffusion from the atmosphere. For example, platforms comprised of PMMA prevented oxygen diffusion from the atmosphere [40, 44]. Gas permeable membranes embedded within the platform enable oxygen diffusion between cells and gas channels. With this control over oxygen concentration, growth patterns of the bacterium *Pseudomonas aeruginosa* under varying oxygen concentrations was studied, demonstrating the capability to study microaerobic and anaerobic conditions [44].

Similarly, a hybrid platform consisting of PDMS and a polycarbonate (PC) film has been developed [41]. The relatively gas impermeable PC film, patterned above the cell channels, reduces diffusion of oxygen from the atmosphere above the device. Meanwhile, the PDMS enables oxygen diffusion from the gas channels to the cell chamber while physically separating the two. Using this platform, migration studies of MDA-MB-231 human breast cancer cells in 3D under hypoxia were performed [41]. To study oxygen uptake rate in hepatocytes and endothelial cells, an oxygen impermeable platform consisting solely of COC has been designed [43]. Due to the nature of the study, this platform did not require gas to be introduced into the system and, thus, did not require an oxygen permeable material. While constructing microfluidic platforms out of gas impermeable materials is promising, these materials are time consuming to pattern and can be difficult to bond and at times challenging to connect to ancillaries.

Microfluidic platforms (Table 3) enable real-time studies of cell behavior such as cell migration, ROS generation, and therapeutic sensitivity under controlled oxygen conditions. In addition, these platforms, reduce equilibration time, increase control of oxygen concentration, enable generation of oxygen gradients, and improve real-time measurements of cell behavior when compared to conventional methods [7]. Still, further work with microfluidic platforms is desired to increase their utility and ease of use in precise control of the oxygen concentration.

Future outlook of microfluidic platforms to control oxygen concentration

Many questions regarding cell behavior in the TME under controlled oxygen conditions remain. Further development of the tools used to control these conditions is needed to enable accurate analysis of cell behavior. Specifically, with respect to microfluidic platforms a number of technical and pragmatic issues still exist. These challenges must be overcome to enable studies leading to a deeper understanding of the TME.

An issue that is beginning to plague microfluidic platforms is “ease of use,” especially pertaining to the requirement of external devices [51, 52]. Toward this end, new techniques, procedures, and platforms have been developed to provide researchers who are not familiar with microfluidics the option to use these valuable tools. For example, surface tension based passive pumping enables addition of fluids and is compatible with micropipettes [53]. A technology that is already available, ‘Kit-On-A-Lid-Assay’, provides self-contained microfluidic cell-based assays, integrating all steps required to perform the assay [54]. Increased understanding of capillary flow in suspended microfluidic platforms offers increased accessibility, functionality, and simplicity of fabrication [55]. Still, the need for gas cylinders and mass flow controllers to introduce gas streams into microfluidic platforms still complicates experiment setup and execution. Hence, new and innovative designs and ideas are required to reduce the complexity of microfluidic platforms for oxygen dependent cell studies.

To move beyond validation of platform studies, scientists must be able to seamlessly integrate these microfluidic platforms into their laboratory toolkit. However, this integration requires familiarity and confidence with the particular microfluidic platform. Implementation of microfluidic platforms in current biology and biochemistry laboratory courses would provide the needed exposure to microfluidics for a broad range of potential users, which would lessen the barrier towards integrating this technology into many biological studies.

Technical issues, such as accurately recapitulating the TME on a microfluidic platform, also must be addressed. The TME directly affects tumor progression and therapeutic resistance, making accurate modeling critical [56, 57]. At present, microfluidic platforms have been developed and applied to study interactions between the different cellular components of the TME [51]. However, to date these platforms have been used primarily to study proof-of-concept biology. To accurately model the TME, further development of imaging techniques that depict a tumor’s cytotype are needed. The tumor cytotype, defined as the identity, quantity, and location of each of the different cell types that make up a tumor, influences how a tumor will evolve over time. Current imaging techniques such as optical coherence tomography (OCT) [58], positron emission tomography (PET) [59, 60], magnetic resonance imaging (MRI) [59], as well as light sheet fluorescence microscopy (LSFM) [61] enable non-invasive imaging of the TME and associated characteristics such as hypoxia and pH. However, these techniques are limited by their chemistry, resolution, or inability to provide quantitative results and typically cannot fully depict the TME. Hence, more detailed analyses and improved imaging of the tumor cytotype is needed for engineers and scientists to more closely mimic these complex tissues, for example within a microfluidic platform.

Another challenge associated with studying cell behavior under controlled oxygen concentrations in microfluidic platforms is the need to develop and integrate methods for endpoint measurements. Traditional endpoint measurements in cell studies performed with microfluidic platforms rely on image analysis for phenotypic behavior such as cell migration or proliferation. To provide more thorough analysis of cell behavior and function under hypoxia, further integration with current biochemical tools is necessary. For example, integrating a microfluidic platform with genetically encoded GFP-based redox sensors could enable measurement of the oxidative state of a cell under hypoxia [8, 62, 63]. Development of methods to quantify secreted molecules would provide insight into cell signaling under hypoxia, however, more research is necessary for current techniques to be adapted under controlled oxygen concentrations [64, 65]. To measure levels of protein, RNA, or DNA, platforms enabling cell lysis for qRT-PCR and western blots off-chip have been developed and qRT-PCR completely on chip has even been performed [66, 67]. Still, challenges with these techniques such as harvesting individual or small groups of cells cultured in complex 3D environments remain.

Beyond cancer and the TME, the stem cell microenvironment [68] as well as diseases such as Alzheimer's [69], rheumatoid arthritis [70], chronic kidney diseases [71], and non-alcoholic fatty liver disease [72] have all been associated with hypoxia. While the context of this article is specific to the TME, one should note that these tools could also be applied to these other hypoxia related microenvironments.

Concluding remarks and future perspectives

Hypoxia affects a number of cellular behaviors in the TME, however, studying these processes in a controlled manner has proven to be challenging. In general, conventional methods enable macroscale studies, but are limited with respect to real-time imaging. More recently, microfluidic platforms have been developed to study cell behavior under controlled oxygen concentrations. Although these platforms have been used primarily in validation studies, compatibility with microscopy provides an opportunity to further study cancer cell biology under hypoxia. However, further technical development of these tools is required for sophisticated biological experiments. Specifically, methods to increase ease of use will provide more facile addition and manipulation of reagents, while more accurate modeling of the TME is necessary to interpret the experimental results and thereby better understand tumor progression and therapeutic efficacy in a relevant system. In addition, to increase adoption of microfluidic platforms, increased training opportunities are necessary, for example through implementation of experiments involving simple microfluidic tools in existing laboratory courses in molecular and cell biology programs.

Box 1

Hypoxia in the tumor microenvironment

The tumor microenvironment consists of populations of transformed cells, stromal cells (*e.g.*, fibroblasts, chondrocytes), vascular cells (*e.g.*, endothelial cells, pericytes) and inflammatory cells (*e.g.*, neutrophils, macrophages), along with acidity (lactic acid from enhanced glycolysis), increased interstitial pressure, and low oxygen partial pressures

[57, 73, 74]. As tumors grow outward away from the local vascular architecture, and become increasingly metabolically active, formation of variable hypoxic regions throughout the solid mass is inevitable [75]. Neoplastic angiogenesis occurs in an attempt to restore oxygenation, but this neo-vasculature is often insufficient and poorly arranged. This leads to the development of even further gradients of oxygen, nutrients, and waste materials [76, 77]. This poses as a therapeutic challenge as tumor hypoxia is associated with resistance to radiotherapy and chemotherapy and is a negative prognostic indicator for a more aggressive phenotype [78, 79]. Furthermore, tumor cells associated with hypoxia are thought to be more malignant and capable of metastasis through avoidance of apoptosis, expression of invasion genes such as matrix metallo-proteases and down regulation of homeostatic genes such as E-cadherin [80-83].

Two aspects of the TME, lower pH and hypoxia, are functionally linked via aerobic glycolysis (Warburg effect), the production of lactate from glucose despite the presence of ample oxygen [84]. When compared to the complete oxidation of glucose to pyruvate through the citric acid cycle and electron transport chain, this metabolic pathway is markedly inefficient [85]. However, aerobic glycolysis likely represents an adaptation to the needs of hyper-proliferative and/or hypoxic cells [74]. Rapidly dividing cells have anabolic needs greater than ATP; glucose can be shuttled away from ATP production to form other macromolecular precursors such as acetyl-CoA, glycolytic intermediates for amino acids, and ribose for nucleotides [86]. Furthermore, other metabolic alterations in cancer cells, such as increased fatty acid synthesis and glutaminolysis, have been suggested as adaptive changes to the constraints of rapid growth in hypoxia. While the molecular switches governing these responses are still being unraveled, tumorigenesis and metabolism are clearly intertwined as all prominent oncogenic alterations have been experimentally linked to changes in metabolism [87]. Ultimately however, the bioenergetic rearrangement towards aerobic glycolysis emerges from a number of factors including oncogene upregulation, tumor suppressor loss, mtDNA mutation, and stabilization of hypoxia inducible factor 1- α (HIF-1 α) in the hypoxic microenvironment [88].

Box 2

The role of hypoxia inducible factor

Hypoxia inducible factor (HIF) is a master regulator of cellular responses to lowered oxygen concentrations. HIF-1 α protein levels are the most frequently used marker of cellular hypoxia. As a DNA-binding transcription factor, HIF induces more than 100 genes, including those coordinating metabolism (especially glycolysis), cell signaling, erythropoiesis, angiogenesis, cell proliferation, and apoptosis [89]. Functional HIF is a heterodimer composed of an α and β subunit. HIF- α contains two oxygen-dependent degradation domains that are hydroxylated via prolyl hydroxylase domain-containing enzymes and subsequently degraded [90, 91]. HIF-1 α levels rise in hypoxia beginning around 5% and peak at 1% oxygen by volume [92]. HIF-1 α stabilization is of particular importance in carcinogenesis, where activity is induced or increased by numerous growth-promoting signals, tumor suppressor loss, oncogene signaling and onco-

metabolite stabilization [93, 94]. Not unsurprisingly, tumors exhibiting higher levels of HIF-1 α have correlated strongly to poorer survival times in many cancers including those of breast, head/neck, esophagus, stomach, and lung [78].

HIF-mediated effects are especially apparent in angiogenesis, in which the transcription factor regulates downstream events such as vascular permeability, extracellular matrix remodeling, endothelial cell migration/proliferation, tube formation, and pericyte interactions [93]. Angiogenesis is of such importance to neoplastic pathogenesis that much of the last half century's cancer research efforts were focused on angiogenesis' role in oxygen availability: understanding molecular underpinnings, revealing roles in tumor mass progression, and ultimately inhibition via receptor antagonism. However, these efforts have not directly led to clinical progress as strongly as predicted. In general, treatment failures seen with angiogenic inhibitors have been attributed to cell population selection towards those that can circumvent the specific angiogenic target (*e.g.*, up/down regulation of angiogenic mediators, reliance on separate factors) and through a pre-existing immunity to the specific therapy (*e.g.*, redundancy in signaling, pre-existing protection from stromal cells/inflammatory cells) [95].

Acknowledgments

Support was provided by the Midwest Cancer Nanotechnology Training Center (M-CNTC), National Institute of Health grants R33-CA137719 and R01-GM083601, and the University of Illinois at Urbana-Champaign.

References

1. Bateman RM, et al. Bench-to-bedside review: microvascular dysfunction in sepsis--hemodynamics, oxygen transport, and nitric oxide. *Crit Care*. 2003; 7:359–373. [PubMed: 12974969]
2. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *Journal of the National Cancer Institute*. 2001; 93:266–276. [PubMed: 11181773]
3. Bache M, et al. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. *Current medicinal chemistry*. 2008; 15:322–338. [PubMed: 18288988]
4. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. *Nature reviews. Cancer*. 2004; 4:437–447.
5. Atkuri KR, et al. Importance of culturing primary lymphocytes at physiological oxygen levels. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:4547–4552. [PubMed: 17360561]
6. Wu D, Yotnda P. Induction and testing of hypoxia in cell culture. *Journal of visualized experiments : JoVE*. 2011
7. Allen CB, et al. Limitations to oxygen diffusion and equilibration in in vitro cell exposure systems in hyperoxia and hypoxia. *American journal of physiology. Lung cellular and molecular physiology*. 2001; 281:L1021–1027. [PubMed: 11557606]
8. Waypa GB, et al. Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells. *Circulation research*. 2010; 106:526–535. [PubMed: 20019331]
9. Abbott A. Cell culture: biology's new dimension. *Nature*. 2003; 424:870–872. [PubMed: 12931155]
10. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. *Nature reviews. Molecular cell biology*. 2006; 7:211–224.
11. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. *Cell*. 2007; 130:601–610. [PubMed: 17719539]

12. Piret JP, et al. CoCl₂, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. *Ann Ny Acad Sci.* 2002; 973:443–447. [PubMed: 12485908]
13. Brahimi-Horn MC, Pouyssegur J. HIF at a glance. *J Cell Sci.* 2009; 122:1055–1057. [PubMed: 19339544]
14. Semenza GL. Hypoxia-inducible factor 1: master regulator of O₂ homeostasis. *Curr Opin Genet Dev.* 1998; 8:588–594. [PubMed: 9794818]
15. Tatum JL, et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. *Int J Radiat Biol.* 2006; 82:699–757. [PubMed: 17118889]
16. Ivan M, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. *Proceedings of the National Academy of Sciences of the United States of America.* 2002; 99:13459–13464. [PubMed: 12351678]
17. Epstein AC, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell.* 2001; 107:43–54. [PubMed: 11595184]
18. Yuan Y, et al. Cobalt inhibits the interaction between hypoxia-inducible factor- α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor- α . *The Journal of biological chemistry.* 2003; 278:15911–15916. [PubMed: 12606543]
19. Leonard SS, et al. Metal-induced oxidative stress and signal transduction. *Free radical biology & medicine.* 2004; 37:1921–1942. [PubMed: 15544913]
20. Stenger C, et al. The cell death response to the ROS inducer, cobalt chloride, in neuroblastoma cell lines according to p53 status. *International journal of oncology.* 2011; 39:601–609. [PubMed: 21687937]
21. Simonsen LO, et al. Cobalt metabolism and toxicology--a brief update. *The Science of the total environment.* 2012; 432:210–215. [PubMed: 22732165]
22. Dai ZJ, et al. Up-regulation of hypoxia inducible factor-1 α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells. *Journal of experimental & clinical cancer research : CR.* 2012; 31:28. [PubMed: 22453051]
23. Yang SJ, et al. Cobalt chloride-induced apoptosis and extracellular signal-regulated protein kinase 1/2 activation in rat C6 glioma cells. *Journal of biochemistry and molecular biology.* 2004; 37:480–486. [PubMed: 15469737]
24. Wang G, et al. Mitochondrial DNA damage and a hypoxic response are induced by CoCl₂ in rat neuronal PC12 cells. *Nucleic acids research.* 2000; 28:2135–2140. [PubMed: 10773083]
25. Li Jeon N, et al. Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device. *Nature biotechnology.* 2002; 20:826–830.
26. Byrne MB, et al. Oscillatory behavior of neutrophils under opposing chemoattractant gradients supports a winner-take-all mechanism. *PloS one.* 2014; 9:e85726. [PubMed: 24465668]
27. Byrne MB, et al. Microfluidic platform for the study of intercellular communication via soluble factor-cell and cell-cell paracrine signaling. *Biomicrofluidics.* 2014; 8
28. Huang CP, et al. Engineering microscale cellular niches for three-dimensional multicellular co-cultures. *Lab on a chip.* 2009; 9:1740–1748. [PubMed: 19495458]
29. Martewicz S, et al. Reversible alteration of calcium dynamics in cardiomyocytes during acute hypoxia transient in a microfluidic platform. *Integrative biology : quantitative biosciences from nano to macro.* 2012; 4:153–164. [PubMed: 22158991]
30. Chen YA, et al. Generation of oxygen gradients in microfluidic devices for cell culture using spatially confined chemical reactions. *Lab on a chip.* 2011; 11:3626–3633. [PubMed: 21915399]
31. Wang L, et al. Construction of oxygen and chemical concentration gradients in a single microfluidic device for studying tumor cell-drug interactions in a dynamic hypoxia microenvironment. *Lab on a chip.* 2013; 13:695–705. [PubMed: 23254684]
32. Lo JF, et al. Oxygen gradients for open well cellular cultures via microfluidic substrates. *Lab on a chip.* 2010; 10:2394–2401. [PubMed: 20559583]
33. Oppgaard SC, Eddington DT. A microfabricated platform for establishing oxygen gradients in 3-D constructs. *Biomedical microdevices.* 2013; 15:407–414. [PubMed: 23344840]

34. Thomas PC, et al. Regulating oxygen levels in a microfluidic device. *Analytical chemistry*. 2011; 83:8821–8824. [PubMed: 21995289]
35. Adler M, et al. Generation of oxygen gradients with arbitrary shapes in a microfluidic device. *Lab on a chip*. 2010; 10:388–391. [PubMed: 20091013]
36. Vollmer AP, et al. Development of an integrated microfluidic platform for dynamic oxygen sensing and delivery in a flowing medium. *Lab on a chip*. 2005; 5:1059–1066. [PubMed: 16175261]
37. Polinkovsky M, et al. Fine temporal control of the medium gas content and acidity and on-chip generation of series of oxygen concentrations for cell cultures. *Lab on a chip*. 2009; 9:1073–1084. [PubMed: 19350089]
38. Lam RH, et al. Culturing aerobic and anaerobic bacteria and mammalian cells with a microfluidic differential oxygenator. *Analytical chemistry*. 2009; 81:5918–5924. [PubMed: 19601655]
39. Peng CC, et al. A microfluidic cell culture array with various oxygen tensions. *Lab on a chip*. 2013; 13:3239–3245. [PubMed: 23784347]
40. Abaci HE, et al. Design and development of microbioreactors for long-term cell culture in controlled oxygen microenvironments. *Biomedical microdevices*. 2012; 14:145–152. [PubMed: 21947550]
41. Funamoto K, et al. A novel microfluidic platform for high-resolution imaging of a three-dimensional cell culture under a controlled hypoxic environment. *Lab on a chip*. 2012; 12:4855–4863. [PubMed: 23023115]
42. Mehta G, et al. Hard top soft bottom microfluidic devices for cell culture and chemical analysis. *Analytical chemistry*. 2009; 81:3714–3722. [PubMed: 19382754]
43. Ochs CJ, et al. Oxygen levels in thermoplastic microfluidic devices during cell culture. *Lab on a chip*. 2013; 14:459–462. [PubMed: 24302467]
44. Skolimowski M, et al. Microfluidic dissolved oxygen gradient generator biochip as a useful tool in bacterial biofilm studies. *Lab on a chip*. 2010; 10:2162–2169. [PubMed: 20571689]
45. Mehta G, et al. Quantitative measurement and control of oxygen levels in microfluidic poly(dimethylsiloxane) bioreactors during cell culture. *Biomedical microdevices*. 2007; 9:123–134. [PubMed: 17160707]
46. Park J, et al. A microsystem for sensing and patterning oxidative microgradients during cell culture. *Lab on a chip*. 2006; 6:611–622. [PubMed: 16652176]
47. Domansky K, et al. Perfused multiwell plate for 3D liver tissue engineering. *Lab on a chip*. 2010; 10:51–58. [PubMed: 20024050]
48. Jiang B, et al. Sodium sulfite is a potential hypoxia inducer that mimics hypoxic stress in *Caenorhabditis elegans*. *J Biol Inorg Chem*. 2011; 16:267–274. [PubMed: 21057967]
49. Oppegard SC, et al. Precise control over the oxygen conditions within the Boyden chamber using a microfabricated insert. *Lab on a chip*. 2010; 10:2366–2373. [PubMed: 20689862]
50. Oppegard SC, et al. Modulating temporal and spatial oxygenation over adherent cellular cultures. *PloS one*. 2009; 4:e6891. [PubMed: 19727397]
51. Young EW. Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment. *Integrative biology : quantitative biosciences from nano to macro*. 2013; 5:1096–1109. [PubMed: 23799587]
52. Sackmann EK, et al. The present and future role of microfluidics in biomedical research. *Nature*. 2014; 507:181–189. [PubMed: 24622198]
53. Walker G, Beebe DJ. A passive pumping method for microfluidic devices. *Lab on a chip*. 2002; 2:131–134. [PubMed: 15100822]
54. Berthier E, et al. Kit-On-A-Lid-Assays for accessible self-contained cell assays. *Lab on a chip*. 2013; 13:424–431. [PubMed: 23229806]
55. Casavant BP, et al. Suspended microfluidics. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110:10111–10116. [PubMed: 23729815]
56. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. *Nature*. 2013; 501:346–354. [PubMed: 24048067]

57. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144:646–674. [PubMed: 21376230]
58. Vakoc BJ, et al. Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. *Nature reviews. Cancer*. 2012; 12:363–368.
59. Sun X, et al. Tumor hypoxia imaging. *Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging*. 2011; 13:399–410. [PubMed: 20838906]
60. Jansen JF, et al. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. *International journal of radiation oncology, biology, physics*. 2010; 77:1403–1410.
61. Verveer PJ, et al. High-resolution three-dimensional imaging of large specimens with light sheet-based microscopy. *Nature methods*. 2007; 4:311–313. [PubMed: 17339847]
62. Lin C, et al. Imaging in real-time with FRET the redox response of tumorigenic cells to glutathione perturbations in a microscale flow. *Integrative biology : quantitative biosciences from nano to macro*. 2011; 3:208–217. [PubMed: 21183971]
63. Kolossov VL, et al. Inhibition of glutathione synthesis distinctly alters mitochondrial and cytosolic redox poise. *Exp Biol Med (Maywood)*. 2014; 239:394–403. [PubMed: 24586100]
64. Eyer K, et al. Implementing enzyme-linked immunosorbent assays on a microfluidic chip to quantify intracellular molecules in single cells. *Analytical chemistry*. 2013; 85:3280–3287. [PubMed: 23388050]
65. Huang N-T, et al. An integrated microfluidic platform for in situ cellular cytokine secretion immunophenotyping. *Lab on a chip*. 2012; 12:4093–4101. [PubMed: 22892681]
66. Sarkar A, et al. Microfluidic probe for single-cell analysis in adherent tissue culture. *Nature communications*. 2014; 5:3421.
67. White AK, et al. High-throughput microfluidic single-cell RT-qPCR. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108:13999–14004. [PubMed: 21808033]
68. Spencer JA, et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. *Nature*. 2014; 508:269–273. [PubMed: 24590072]
69. Ogunshola OO, Antoniou X. Contribution of hypoxia to Alzheimer's disease: is HIF-1 α a mediator of neurodegeneration? *Cellular and molecular life sciences : CMLS*. 2009; 66:3555–3563. [PubMed: 19763399]
70. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. *Current opinion in rheumatology*. 2005; 17:293–298. [PubMed: 15838239]
71. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. *Kidney Int*. 2008; 74:867–872. [PubMed: 18633339]
72. Aron-Wisnewsky J, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. *Journal of hepatology*. 2012; 56:225–233. [PubMed: 21703181]
73. Helmlinger G, et al. Interstitial pH and pO₂ gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nature medicine*. 1997; 3:177–182.
74. Ferreira LMR. Cancer metabolism: The Warburg effect today. *Experimental and Molecular Pathology*. 2010; 89:372–380. [PubMed: 20804748]
75. Hoeckel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. *Journal of the National Cancer Institute (Bethesda)*. 2001; 93:266–276.
76. Iyer AK, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. *Drug Discovery Today*. 2006; 11:812–818. [PubMed: 16935749]
77. Maeda H, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. *Journal of Controlled Release*. 2000; 65:271–284. [PubMed: 10699287]
78. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. *Cancer metastasis reviews*. 2007; 26:225–239. [PubMed: 17440684]
79. Axelson H, et al. Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. *Seminars in cell & developmental biology*. 2005; 16:554–563. [PubMed: 16144692]

80. Rundqvist H, Johnson RS. Tumour oxygenation: implications for breast cancer prognosis. *Journal of Internal Medicine*. 2013; 274:105–112. [PubMed: 23844914]
81. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. *Cancer and Metastasis Reviews*. 2007; 26:333–339. [PubMed: 17458506]
82. Zhang L, Hill RP. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. *Cancer research*. 2004; 64:4180–4189. [PubMed: 15205329]
83. Munoz-Najar UM, et al. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. *Oncogene*. 2006; 25:2379–2392. [PubMed: 16369494]
84. Dakubo, GD. *The Warburg phenomenon and other metabolic alterations of cancer cells*. Springer; 2010.
85. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. *Annual review of cell and developmental biology*. 2011; 27:441–464.
86. Vander Heiden MG, et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009; 324:1029–1033. [PubMed: 19460998]
87. Dakubo GD. *The Warburg Phenomenon and Other Metabolic Alterations of Cancer Cells*. 2010
88. Jang M, et al. Cancer cell metabolism: implications for therapeutic targets. *Experimental and Molecular Medicine*. 2013:45.
89. Maxwell PH. Hypoxia-inducible factor as a physiological regulator. *Experimental Physiology*. 2005; 90:791–797. [PubMed: 16157658]
90. Greer SN, et al. The updated biology of hypoxia-inducible factor. *Embo Journal*. 2012; 31:2448–2460. [PubMed: 22562152]
91. Hellwig-Burgel T, et al. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. *Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research*. 2005; 25:297–310.
92. Zhou W, et al. Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct. *PloS one*. 2011; 6:e27460. [PubMed: 22132102]
93. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. *Critical Reviews in Oncology Hematology*. 2006; 59:15–26.
94. King A, et al. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. *Oncogene*. 2006; 25:4675–4682. [PubMed: 16892081]
95. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nature reviews. Cancer*. 2008; 8:592–603.
96. Cox ME, Dunn B. Oxygen Diffusion in Poly(Dimethyl Siloxane) Using Fluorescence Quenching . 1. Measurement Technique and Analysis. *J Polym Sci Pol Chem*. 1986; 24:621–636.
97. Wang B, Ogilby PR. Activation barriers for oxygen diffusion in polystyrene and polycarbonate glasses: Effects of codissolved argon, helium, and nitrogen. *Can J Chem*. 1995; 73:1831–1840.
98. Hu CC, et al. Gas separation properties in cyclic olefin copolymer membrane studied by positron annihilation, sorption, and gas permeation. *J Membrane Sci*. 2006; 274:192–199.
99. Klinger M, et al. Effect of Polymer Cross-Links on Oxygen Diffusion in Glassy PMMA Films. *Acs Appl Mater Inter*. 2009; 1:661–667.
100. Eken M, et al. Diffusion of Oxygen into Irradiated Polypropylene Films. *Radiat Phys Chem*. 1995; 46:809–812.

Highlights

- Hypoxia, low levels of oxygen concentration, affects cell behavior and fate.
- Real-time cell behavior studies in hypoxia are difficult with conventional methods.
- Advanced microfluidic platforms allow for precise control over oxygen concentration.
- Microfluidic platforms enable real-time imaging of cell behavior under hypoxia.

Figure 1.

Illustrations of three conventional methods that enable control of oxygen concentration during cell studies: (A) a gas-controlled incubator, (B) a glove box, and (C) biochemical induction of a pseudo-hypoxic state.

Figure 2.

Microfluidic platforms that enable control over oxygen concentration, shown in top down view (left) and cross sectional view (right). Dashed line indicates where the cross-section was made. The different platforms can control oxygen concentration by (A) introducing oxygen scavenging chemicals, (B) altering the diffusional distance of oxygen, or (C) incorporating relatively oxygen impermeable materials.

Table 1

Partial oxygen pressure (pO₂) of solid tumors and the associated surrounding healthy tissue. All pO₂ values are combined medians of individual values that were measured in mmHg using an oxygen electrode (modified from [4]).

Tumor type	Median diseased pO₂	Median Health pO₂
Glioblastoma	4.9 - 5.6	-
Head and neck carcinoma	12 - 15	40 - 51
Lung cancer	7.5	38
Breast cancer	10	-
Pancreatic cancer	2.7	52
Cervical cancer	3.0 - 5.0	51
Prostate cancer	2.7	52
Soft-tissue sarcoma	6.2 - 18	-

Table 2

Oxygen diffusivity in materials commonly used for fabrication of microfluidic platforms.

Material	Oxygen Diffusivity ($10^{-11} \text{ m}^2/\text{s}$)	Refs
Poly(dimethylsiloxane) (PDMS)	400	[96]
Polycarbonate (PC)	2.0	[97]
Polystyrene (PS)	4.0	[97]
Cyclic olefin copolymer (COC)	0.46	[43, 98]
Poly(methy methacrylate) (PMMA)	0.25	[99]
Polypropylene (PP)	3.0	[100]

Table 3

Summary of reported microfluidic platforms that enable control of oxygen concentration in cell studies.

Material used	Cells in 3D?	Device features	Refs.
Introducing oxygen scavenging chemicals for oxygen control			
PDMS	No	Chemical reactions generate oxygen gradients	[30]
PDMS	No	Top of platform open to atmosphere and oxygen scavenging chemicals below cell chamber	[39]
PDMS	No	Oxygen scavenging chemicals in cell chamber	[31]
Gas supply channels placed adjacent to cell chambers for oxygen control			
PDMS	No	Gas channel above or below cell chamber	[29, 35, 37, 38]
PDMS	No	Top of platform open to the atmosphere	[32]
PDMS	No	Valves actuated by Braille bin to circulate media	[45]
PDMS	No	Boyden chamber insert coated with Parylene-C	[49]
PDMS	Yes	Gas channels above and below cell chamber	[33]
PDMS	No	Insert for well plates	[50]
PDMS	No	Oxygen controlled with pre-equilibrated water	[34]
Platforms fabricated out of oxygen impermeable materials for oxygen control			
PMMA	No	PMMA exterior with gas permeable membrane	[40]
PC, ROMS	Yes	PC film patterned above PDMS channels	[41]
COC, PS	No	Patterned channels in COC and PS	[42]
COC, PMP	Yes	Completely composed of COC or PMP	[43]
PMMA	No	PDMS channels with PMMA exterior	[44]